{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:13:42Z","timestamp":1782990822549,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["academicradiology.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Radiology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.acra.2021.01.024","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T09:07:32Z","timestamp":1614416852000},"page":"S157-S166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"S1","title":["Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization"],"prefix":"10.1016","volume":"28","author":[{"given":"Shu-Jung","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Pei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Ling","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Feng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Gang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3236-5878","authenticated-orcid":false,"given":"Rong-Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.acra.2021.01.024_bib0003","first-page":"1683","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study","volume":"3","author":"Akinyemiju","year":"2015","journal-title":"Jama Oncol"},{"issue":"1","key":"10.1016\/j.acra.2021.01.024_bib0004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.acra.2021.01.024_bib0005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.acra.2021.01.024_bib0006","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.acra.2021.01.024_bib0007","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/2050640617716597","article-title":"Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease","volume":"6","author":"Kirstein","year":"2018","journal-title":"United Eur Gastroenterol J"},{"issue":"3","key":"10.1016\/j.acra.2021.01.024_bib0008","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3892\/etm.2012.611","article-title":"Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma","volume":"4","author":"Nishikawa","year":"2012","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/j.acra.2021.01.024_bib0009","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1148\/radiol.12111550","article-title":"Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib","volume":"263","author":"Pinter","year":"2012","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.acra.2021.01.024_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214613","article-title":"Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection","volume":"14","author":"Jeon","year":"2019","journal-title":"Plos One"},{"issue":"3","key":"10.1016\/j.acra.2021.01.024_bib0011","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12072-017-9792-3","article-title":"Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization","volume":"11","author":"Lee","year":"2017","journal-title":"HepatoL Int"},{"issue":"5","key":"10.1016\/j.acra.2021.01.024_bib0012","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.bjc.6602742","article-title":"Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression","volume":"93","author":"Ota","year":"2005","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.acra.2021.01.024_bib0013","first-page":"1990","article-title":"Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion","volume":"106","author":"Obi","year":"2006","journal-title":"Cancer-Am Cancer Soc"},{"issue":"2","key":"10.1016\/j.acra.2021.01.024_bib0014","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1872-034X.2011.00905.x","article-title":"5-fluorouracil arterial infusion\u202f+\u202finterferon therapy for highly advanced hepatocellular carcinoma: a multicenter, randomized, phase II study","volume":"42","author":"Monden","year":"2012","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.acra.2021.01.024_bib0015","first-page":"129","article-title":"Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma","volume":"110","author":"Park","year":"2007","journal-title":"Cancer-Am Cancer Soc"},{"issue":"5","key":"10.1016\/j.acra.2021.01.024_bib0016","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1872-034X.2008.00338.x","article-title":"Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma","volume":"38","author":"Yoshikawa","year":"2008","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.acra.2021.01.024_bib0017","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00280-013-2222-x","article-title":"A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"72","author":"Ikeda","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.acra.2021.01.024_bib0018","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000315244","article-title":"Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma","volume":"78","author":"Ueshima","year":"2010","journal-title":"Oncology"},{"issue":"7","key":"10.1016\/j.acra.2021.01.024_bib0019","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/bjc.2013.542","article-title":"Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide survey of primary liver cancer in Japan","volume":"109","author":"Nouso","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.acra.2021.01.024_bib0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40880-017-0251-2","article-title":"Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study","volume":"36","author":"He","year":"2017","journal-title":"Chin J Cancer"},{"issue":"7","key":"10.1016\/j.acra.2021.01.024_bib0021","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/bjc.2013.542","article-title":"Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan","volume":"109","author":"Nouso","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.acra.2021.01.024_bib0022","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/1078-0432.CCR-18-0847","article-title":"A Phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma","volume":"25","author":"Goyal","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.acra.2021.01.024_bib0023","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41416-019-0443-4","article-title":"Sorafenib alone vs. sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial","volume":"120","author":"Assenat","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.acra.2021.01.024_bib0024","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.4052","article-title":"Potential areas of interest in a trial of sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for hepatocellular carcinoma","author":"Palmieri","year":"2019","journal-title":"Jama Oncol"},{"issue":"1","key":"10.1016\/j.acra.2021.01.024_bib0025","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1186\/s12885-019-6198-8","article-title":"Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial","volume":"19","author":"Kondo","year":"2019","journal-title":"Bmc Cancer"},{"issue":"4","key":"10.1016\/j.acra.2021.01.024_bib0026","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.acra.2021.01.024_bib0027","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00535-014-0978-3","article-title":"A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis","volume":"50","author":"Song","year":"2015","journal-title":"J Gastroenterol"},{"issue":"12","key":"10.1016\/j.acra.2021.01.024_bib0028","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1634\/theoncologist.2015-0196","article-title":"Sorafenib with and without transarterial chemoembolization for advanced hepatocellular carcinoma with main portal vein tumor thrombosis: a retrospective analysis","volume":"20","author":"Zhang","year":"2015","journal-title":"Oncologist"},{"issue":"10126","key":"10.1016\/j.acra.2021.01.024_bib0029","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.acra.2021.01.024_bib0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000502905","article-title":"A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.acra.2021.01.024_bib0031","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000503031","article-title":"Post-progression treatment eligibility of unresectable hepatocellular carcinoma patients treated with lenvatinib","volume":"9","author":"Hiraoka","year":"2020","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.acra.2021.01.024_bib0032","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","article-title":"Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies","volume":"30","author":"Marelli","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"7","key":"10.1016\/j.acra.2021.01.024_bib0033","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/hepr.13335","article-title":"Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma >\/=10 cm","volume":"49","author":"Miyayama","year":"2019","journal-title":"Hepatol Res"},{"issue":"7","key":"10.1016\/j.acra.2021.01.024_bib0034","first-page":"3523","article-title":"Comparison of outcome of hepatic arterial infusion chemotherapy and sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization","volume":"36","author":"Hatooka","year":"2016","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.acra.2021.01.024_bib0035","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000365993","article-title":"Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization","volume":"87","author":"Ogasawara","year":"2014","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.acra.2021.01.024_bib0036","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","article-title":"Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma","volume":"52","author":"Ikeda","year":"2017","journal-title":"J Gastroenterol"},{"issue":"13","key":"10.1016\/j.acra.2021.01.024_bib0037","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/hepr.13232","article-title":"Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma","volume":"48","author":"Kawaoka","year":"2018","journal-title":"HEPATOL RES"},{"key":"10.1016\/j.acra.2021.01.024_bib0038","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/bjc.1998.429","article-title":"Ongoing and unsaid on oxaliplatin: the hope","volume":"77","author":"Cvitkovic","year":"1998","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.acra.2021.01.024_bib0039","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1517\/13543780903292626","article-title":"Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth","volume":"18","author":"Wang","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"10.1016\/j.acra.2021.01.024_bib0040","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s00270-019-02406-3","article-title":"Hepatic arterial infusion chemotherapy using Oxaliplatin plus 5-fluorouracil versus transarterial chemoembolization\/embolization for the treatment of advanced hepatocellular carcinoma with major portal vein tumor thrombosis","volume":"43","author":"Hu","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.acra.2021.01.024_bib0041","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jvir.2018.09.004","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin in hepatocellular cancer with extrahepatic spread","volume":"30","author":"Lyu","year":"2019","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"10.1016\/j.acra.2021.01.024_bib0042","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","article-title":"Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma","volume":"69","author":"Lyu","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.acra.2021.01.024_bib0043","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","article-title":"Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.acra.2021.01.024_bib0044","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial","volume":"5","author":"He","year":"2019","journal-title":"Jama Oncol"},{"issue":"2","key":"10.1016\/j.acra.2021.01.024_bib0045","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000471807","article-title":"Role of albumin in growth inhibition in hepatocellular carcinoma","volume":"93","author":"Ba\u011f\u0131rsak\u00e7\u0131","year":"2017","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.acra.2021.01.024_bib0046","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.5301\/ijbm.5000300","article-title":"Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients","volume":"32","author":"Carr","year":"2017","journal-title":"Int J Biol Markers"},{"issue":"2","key":"10.1016\/j.acra.2021.01.024_bib0047","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1053\/gast.2002.30983","article-title":"Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein","volume":"122","author":"Okuda","year":"2002","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.acra.2021.01.024_bib0048","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/hep.26256","article-title":"The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"57","author":"Sieghart","year":"2013","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.acra.2021.01.024_bib0049","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1365-2036.2011.04823.x","article-title":"Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib","volume":"34","author":"Pinter","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"19","key":"10.1016\/j.acra.2021.01.024_bib0050","first-page":"4475","article-title":"Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors","volume":"117","author":"Uchino","year":"2011","journal-title":"Cancer-Am Cancer Soc"},{"issue":"1","key":"10.1016\/j.acra.2021.01.024_bib0051","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","article-title":"Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma","volume":"69","author":"Lyu","year":"2018","journal-title":"J Hepatol"},{"issue":"28","key":"10.1016\/j.acra.2021.01.024_bib0052","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2012.44.5643","article-title":"Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia","volume":"31","author":"Qin","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Academic Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633221000337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1076633221000337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:50:56Z","timestamp":1761036656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1076633221000337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":50,"alternative-id":["S1076633221000337"],"URL":"https:\/\/doi.org\/10.1016\/j.acra.2021.01.024","relation":{},"ISSN":["1076-6332"],"issn-type":[{"value":"1076-6332","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization","name":"articletitle","label":"Article Title"},{"value":"Academic Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acra.2021.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}